$580 Million is the total value of Aisling Capital LLC's 22 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LOXO | Buy | LOXO ONCOLOGY INC | $108,006,000 | +79.0% | 3,796,362 | +10.0% | 18.63% | +75.6% |
| CEMP | CEMPRA INC | $68,270,000 | +11.8% | 2,193,060 | 0.0% | 11.77% | +9.7% | |
| ZLTQ | Sell | ZELTIQ AESTHETICS INC | $60,014,000 | -28.0% | 2,103,528 | -19.2% | 10.35% | -29.4% |
| AIMT | Buy | AIMMUNE THERAPEUTICS INC. | $55,166,000 | -22.7% | 2,990,000 | +6.0% | 9.51% | -24.2% |
| ESPR | ESPERION THERAPEUTICS INC. | $36,442,000 | -5.6% | 1,637,125 | 0.0% | 6.28% | -7.4% | |
| TTOO | Buy | T2 BIOSYSTEMS INC | $30,971,000 | +40.1% | 2,830,992 | +12.2% | 5.34% | +37.4% |
| ADMA | ADMA BIOLOGICS INC | $29,118,000 | -3.5% | 3,608,171 | 0.0% | 5.02% | -5.3% | |
| AGRX | AGILE THERAPEUTICS INC" | $29,122,000 | +44.8% | 2,983,797 | 0.0% | 5.02% | +42.0% | |
| DERM | Sell | DERMIRA INC | $28,409,000 | +10.4% | 820,823 | -25.5% | 4.90% | +8.4% |
| VSAR | VERSARTIS INC | $28,244,000 | +7.5% | 2,279,568 | 0.0% | 4.87% | +5.4% | |
| TRXC | TRANSENTERIX INC. | $20,673,000 | +9.7% | 8,335,819 | 0.0% | 3.56% | +7.6% | |
| CTLT | CATALENT INC | $17,913,000 | +3.0% | 715,673 | 0.0% | 3.09% | +1.0% | |
| CDTX | Sell | CIDARA THERAPEUTICS INC. | $17,494,000 | +34.9% | 1,019,455 | -0.0% | 3.02% | +32.3% |
| CYNA | Buy | CYNAPSUS THERAPEUTICS INC. | $15,617,000 | -1.0% | 1,021,381 | +4.7% | 2.69% | -2.8% |
| PRTK | PARATEK PHARMACEUTICALS INC | $12,950,000 | -0.2% | 682,680 | 0.0% | 2.23% | -2.1% | |
| XENT | INTERSECT ENT INC | $7,875,000 | -3.8% | 350,000 | 0.0% | 1.36% | -5.7% | |
| PTX | PERNIX THERAPEUTICS HLDGS IN | $5,930,000 | -6.6% | 2,010,000 | 0.0% | 1.02% | -8.4% | |
| CMRX | Sell | CHIMERIX INC. | $4,233,000 | -84.7% | 472,943 | -34.6% | 0.73% | -85.0% |
| PERNIX THERAPEUTICS HLDGS INCdebt | $1,450,000 | -19.8% | 2,500,000 | 0.0% | 0.25% | -21.4% | ||
| EVAR | LOMBARD MED INC | $1,197,000 | -62.2% | 886,363 | 0.0% | 0.21% | -62.9% | |
| ROKA | Sell | ROKA BIOSCIENCE INC | $704,000 | -55.5% | 572,720 | -29.5% | 0.12% | -56.5% |
| SRNE | Sell | SORRENTO THERAPEUTICS INC | $34,000 | -98.9% | 3,855 | -98.9% | 0.01% | -98.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TRANSENTERIX INC. | 22 | Q3 2019 | 12.1% |
| CHIMERIX INC. | 21 | Q4 2018 | 19.4% |
| ADMA BIOLOGICS INC. | 20 | Q3 2019 | 35.5% |
| LOXO ONCOLOGY INC. | 18 | Q4 2018 | 80.9% |
| AIMMUNE THERAPEUTICS INC. | 17 | Q3 2019 | 68.7% |
| CIDARA THERAPEUTICS INC. | 17 | Q3 2019 | 4.1% |
| AGILE THERAPEUTICS INC. | 16 | Q1 2018 | 5.5% |
| ZELTIQ AESTHETICS INC | 14 | Q3 2017 | 16.3% |
| ESPERION THERAPEUTICS INC NE | 14 | Q3 2017 | 24.9% |
| VERSARTIS INC | 13 | Q2 2017 | 16.2% |
View Aisling Capital LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-13 |
| 13F-HR | 2019-08-08 |
| 13F-HR | 2019-05-07 |
| 13F-HR | 2019-02-11 |
| 13F-HR | 2018-11-05 |
| 13F-HR | 2018-08-13 |
| 13F-HR | 2018-05-14 |
| 13F-HR | 2018-02-07 |
| 13F-HR | 2017-11-09 |
| 13F-HR | 2017-08-14 |
View Aisling Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.